Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N
NTHI.OQ - NeOnc Technologies Holdings Inc
NeOnc Technologies Holdings Inc to Discuss Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma
Aug 12, 2026 / 12:30PM GMT
=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Thank you and good morning everyone.
Welcome to the Neon Technologies Investment Conference Hall to discuss top-line results. From the Phase 284 of our Neo100-01 clinical file, the recurrent IVH1 nutrient hybrid glion.
Joining me on the call today, we have Amir Hetznerpour, our Chief Executive Officer and Executive Chairman.
We also have Dr. Thomas Chance by right, who's our founder and Chief Medical Officer and Chief Scientific Officer.
We also have Dr.
Josh Meeman, who's our Chief Clinical Officer.
My name is Keith LeGarnette. I serve as a Chief Financial Officer. Today, we
Trustpilot
